This trial is evaluating whether 18F-C-SNAT4 will improve 1 primary outcome and 5 secondary outcomes in patients with Lung Cancers. Measurement will happen over the course of 1 day.
This trial requires 20 total participants across 3 different treatment groups
This trial involves 3 different treatments. 18F-C-SNAT4 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Participation is compensated
You will be compensated for participating in this trial.
Lung cancer is frequently treated using a range of treatments, including combinations of different forms of therapy. The most common forms of treatment are surgery, chemotherapy, and radiation therapy.
The most frequent age to present with [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) is age 70 or older, with both women and men being diagnosed. Most patients live a decade or more after diagnosis which makes it an important disease to detect before it is diagnosed too late. The majority of patients with lung cancer are diagnosed at an advanced stage, as is often the case with all cancers. Survival is low despite advances in treatment. Lung cancer is a curable disease with the advancement of surgery, chemotherapy and radiation as well as newer targeted therapies being developed. Survival is affected by the cancer stage but is not modified by tumor grade.
About 235,000 lung cancers will be diagnosed in 2022. This is a substantial increase from the number of lung cancers diagnosed in 2000 (140,000). The increase is particularly noticeable among men and current smokers, and among younger adults. Because smoking increases a person's risk of developing lung cancers during all age ranges, it is anticipated that smoking prevalence will continue to increase during this period.
Recent findings of this study confirm the poor response to treatment and poor prognosis presented with lung cancer patients in the PSA era. The data also suggest that most patients with lung cancer do not survive beyond an average of six months.
Symptoms include cough with shortness of breath, especially dyspnoea. Some symptoms are more frequently associated with squamous cell carcinomas, while symptoms of adenocarcinoma are more likely to manifest in the presence of chest pain. Symptoms are present in 5% of people aged sixty and over. Patients with recurrent symptoms of lung cancers are more likely to show symptoms from recurrence. Lymphadenopathy is a significant indicator of adenocarcinoma. Other findings associated with lung cancers include chest deformities and palpable mass.
Tobacco is the major causative factor of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) in our population. The role of secondhand smoke and secondhand food are of more recent acceptance. There is a high frequency of lung cancer in smokers who started working at younger ages and in people with a family history of the disease. Other factors, either nutritional or occupational, contribute to lung cancer risk. Exposure to secondhand tobacco smoking and secondhand food can adversely influence the body's immune system, which is thought to have a role in cancer development.
The initial response to (18)F-c-snat4 PET scans in lung cancer is usually very poor in patients with lung tumors. When imaging is performed for the evaluation or management of pulmonary symptoms, c-snat4 PET scanning can be used for the differential diagnosis between benign and malignant disorders.
18F-c-snat4 PET-CT, performed with PET/CT, showed an improvement in SUVmax of lung tumor lesions in 13 of 13 patients, and in 10 of 13 patients in the comparison group. The data of this study suggest that 18f-c-snat4 PET-CT is a promising tool to monitor the disease burden and for guiding palliative therapies.
The most frequent side effects included headache, fatigue, nausea and dyspepsia. The most frequently observed adverse event was a transient increase in serum creatinine level, without any association with dose or duration of treatment. The most common adverse drug reactions (ADRs) were diarrhea, asthenia, and dizziness.
Lung cancers are the second leading cause of cancer deaths in North America. Cancer of the lung presents in 3 ways: (1) non-small-cell lung carcinoma, which represents 85% of lung cancers; (2) small-cell lung carcinoma, which represents 2.5% of cases; and (3) lung adenocarcinoma, which accounts for ~2% of all lung cancer cases. Survival in cases of non-small-cell lung cancer is affected by the severity of disease and the overall state of the person at the time of diagnosis.
Our clinical observation of a single person with metastatic colon cancer having a positive response to a single administration of 18f-c-snat4 suggests this agent may be effective in colon cancers as well. Further study in this patient is warranted.
[In the US] the age of onset of lung cancers has declined slightly since the 1970s (about 5 years earlier), reaching their peak prevalence about three decades later. This decline likely reflects changes in exposure patterns and the aging of the population, and the relative increase in numbers of smokers.